Immunovia Publ Valuation
| IMMNOV Stock | SEK 0.47 0.02 4.08% |
Immunovia Publ is overvalued. Immunovia publ AB retains a regular Real Value of kr0.45 per share. The prevalent price of the firm is kr0.47. Our model calculates the value of Immunovia publ AB from evaluating the firm fundamentals such as Return On Equity of -0.38, return on asset of -0.26, and Shares Outstanding of 22.63 M as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Immunovia Publ's price fluctuation is out of control at this time. Calculation of the real value of Immunovia publ AB is based on 3 months time horizon. Increasing Immunovia Publ's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Immunovia Publ is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Immunovia Stock. However, Immunovia Publ's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.47 | Real 0.45 | Hype 0.47 |
The real value of Immunovia Stock, also known as its intrinsic value, is the underlying worth of Immunovia publ AB Company, which is reflected in its stock price. It is based on Immunovia Publ's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Immunovia Publ's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Immunovia publ AB helps investors to forecast how Immunovia stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Immunovia Publ more accurately as focusing exclusively on Immunovia Publ's fundamentals will not take into account other important factors: Immunovia Publ Total Value Analysis
Immunovia publ AB is currently expected to have takeover price of 536.89 M with market capitalization of 479.62 M, debt of 27.16 M, and cash on hands of 359.85 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Immunovia Publ fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
536.89 M | 479.62 M | 27.16 M | 359.85 M |
Immunovia Publ Investor Information
About 36.0% of the company shares are held by company insiders. The book value of Immunovia Publ was currently reported as 13.09. The company recorded a loss per share of 7.81. Immunovia publ AB had not issued any dividends in recent years. Immunovia publ AB is not in a good financial situation at the moment. It has a very high risk of going through financial straits in February.Immunovia Publ Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Immunovia Publ has an asset utilization ratio of 0.17 percent. This suggests that the Company is making kr0.001709 for each dollar of assets. An increasing asset utilization means that Immunovia publ AB is more efficient with each dollar of assets it utilizes for everyday operations.Immunovia Publ Ownership Allocation
Immunovia publ AB has a total of 22.63 Million outstanding shares. Immunovia Publ secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Immunovia Publ Profitability Analysis
The company reported the revenue of 844 K. Net Loss for the year was (166.63 M) with profit before overhead, payroll, taxes, and interest of 15.81 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Immunovia Publ's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Immunovia Publ and how it compares across the competition.
About Immunovia Publ Valuation
The stock valuation mechanism determines Immunovia Publ's current worth on a weekly basis. Our valuation model uses a comparative analysis of Immunovia Publ. We calculate exposure to Immunovia Publ's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Immunovia Publ's related companies.Immunovia AB , a molecular diagnostics company, develops and commercializes diagnostic tools for cancer and autoimmune diseases in Sweden and internationally. Immunovia AB was founded in 2007 and is headquartered in Lund, Sweden. Immunovia operates under Diagnostics Research classification in Sweden and is traded on Stockholm Stock Exchange. It employs 46 people.
8 Steps to conduct Immunovia Publ's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Immunovia Publ's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Immunovia Publ's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Immunovia Publ's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Immunovia Publ's revenue streams: Identify Immunovia Publ's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Immunovia Publ's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Immunovia Publ's growth potential: Evaluate Immunovia Publ's management, business model, and growth potential.
- Determine Immunovia Publ's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Immunovia Publ's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Immunovia Stock analysis
When running Immunovia Publ's price analysis, check to measure Immunovia Publ's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovia Publ is operating at the current time. Most of Immunovia Publ's value examination focuses on studying past and present price action to predict the probability of Immunovia Publ's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovia Publ's price. Additionally, you may evaluate how the addition of Immunovia Publ to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Transaction History View history of all your transactions and understand their impact on performance |